Inactive Instrument

Varian Medical Systems, Inc.

Equities

VAR

US92220P1057

WeissLaw LLP : Reminds VAR, LVGO, and GLIBA Shareholders About Its Ongoing Investigations

September 01, 2020 at 07:42 pm EDT

NEW YORK, Sept. 1, 2020 /PRNewswire/ --

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Varian Medical Systems, Inc. (NYSE: VAR)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Varian Medical Systems, Inc. (NYSE: VAR) in connection with the proposed acquisition of the company by Siemens Healthineers AG. Under the terms of the agreement, VAR shareholders will receive $177.50 in cash for each share of VAR common stock that they own. If you own VAR shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/varian-medical-systems-inc/

Livongo Health, Inc. (NASDAQ: LVGO)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Livongo Health, Inc. (NASDAQ: LVGO) in connection with the proposed merger of the company with Teladoc Health, Inc. ("TDOC"). Under the terms of the agreement, LVGO shareholders will receive 0.5920 TDOC shares and $11.33 in cash for each share of LVGO common stock they own, representing implied per-share merger consideration of $139.02 based upon TDOC's August 31, 2020 closing price of $215.69. If you own LVGO shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/livongo-health-inc/

GCI Liberty, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GCI Liberty, Inc. in connection with the proposed acquisition of the company by Liberty Broadband. Under the terms of the transaction, Series A GLIBA shareholders will receive 0.580 shares of Liberty Broadband's Series C common stock for each share of GLIBA stock they hold, representing implied per-share merger consideration of approximately $81.25 based upon Liberty Broadband's August 31, 2020 closing price of $140.09. If you own GLIBA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/gci-liberty-inc/

View original content to download multimedia:http://www.prnewswire.com/news-releases/weisslaw-llp-reminds-var-lvgo-and-gliba-shareholders-about-its-ongoing-investigations-301122489.html

SOURCE WeissLaw LLP

Latest news about Varian Medical Systems, Inc.

Varian Collaborates with BaraSeen Medical Company to Pave the Way for Advanced Cancer Treatment in Saudi Arabia with Sustainable Halcyon Technology	10:16am	CI
Varian and Nova Scotia Health Form First Multi-Disciplinary Oncology Partnership to Catalyze Advancements in Cancer Care	Jan. 04	CI
Varian Medical Systems, Inc. acquired Aspekt Solutions.	23-09-25	CI
Varian Announces First Participant Treated in RADIATE-VT Clinical Trial of Cardiac Radioablation for Patients with Refractory Ventricular Tachycardia	23-05-19	CI
Varian Collaborating with Nova Scotia Health to Transform Cancer Care	23-02-17	CI
Varian Receives Investigational Device Exemption for Flash Technology Clinical Trial, FAST-02	22-06-27	CI
Adaptiiv Collaborates with HP and Varian to Enhance Personalization in Radiation Oncology with 3D Printed Medical Devices	22-05-06	CI
Oulu University Hospital in Finland Enters Long-Term Strategic Partnership with Varian and Siemens Healthineers	22-01-19	CI
Varian and Icon Oncology Partner to Establish Value-Based Cancer Treatment Hub for Southern Africa	21-12-14	CI
Varian and the Cincinnati Children's/UC Health Proton Therapy Center Complete Enrollment of FAST-01, First Human Clinical Trial of FLASH Therapy for Cancer	21-10-25	CI
Varian Medical Systems, Inc. Receives FDA "Breakthrough Device Designation" For Embozene® Microspheres For Genicular Artery Embolization For Symptomatic Knee Osteoarthritis	21-10-13	CI
Elekta : Medical equipment maker Elekta sees higher supply chain costs, shares fall	21-08-25	RE
Icon Group First in World to Adopt New Multi-Disciplinary Oncology Information System from Varian	21-08-05	CI
Siemens : Targets Higher Full-Year Profit As Demand Surge Beats Supply Chain Woes	21-08-05	MT
Siemens Backs Fiscal Year 2021 Outlook, Including Varian Deal	21-06-24	DJ
Varian Receives FDA "Breakthrough Device Designation" for its Cardiac Radioablation System for Treatment of Refractory Ventricular Tachycardia (VT)	21-05-26	CI
Siemens : Raises FY21 Outlook As Fiscal H1 Profit Doubles	21-05-07	MT
Siemens Healthineers : Strong COVID-19 Antigen Test Sales Prompt Siemens Healthineers Full-Year Guidance Boost	21-05-03	MT
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500 EQUAL WEIGHTED	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P TMI Index	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P Global BMI Index	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500 Growth	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P Global 1200	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500 Health Care Equipment & Services (Industry Group)	21-04-20	CI

Chart Varian Medical Systems, Inc.

Duration

Period

More charts

Company Profile

Varian Medical Systems, Inc. is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, cardiac radioablation, radiosurgery, proton therapy and brachytherapy. The Company also has Varian Particle Therapy (VPT) and the operations of the Ginzton Technology Center (GTC). Its VPT business develops, designs, manufactures, sells and services products and systems for delivering proton therapy, another form of external beam radiotherapy using proton beams for the treatment of cancer. Its ProBeam system is capable of delivering intensity modulated proton therapy (IMPT) using pencil beam scanning technology. Its ProBeam Compact is a single room proton therapy product. Through its subsidiary, Cooperative CL Enterprises, the Company distributes radiotherapy equipments in Taiwan.

Sector

More about the company